1.13
-0.01(-0.88%)
Currency In USD
Address
8 Clarke Drive
Princeton, NJ 08512
United States of America
Phone
609 642 6670
Website
Sector
Healthcare
Industry
Biotechnology
Employees
47
First IPO Date
September 25, 2020
| Name | Title | Pay | Year Born |
| David H. Mack | Co-Founder, CEO, President & Director | 943,066 | 1962 |
| Arnold J. Levine | Co-Founder, Independent Director & Member of Scientific Advisory Board | 140,000 | 1940 |
| Michael Carulli | Chief Financial Officer | 532,801 | 1974 |
| Deepika Jalota | Chief Development Officer | 638,364 | 1977 |
| Binh Vu | Senior Vice President of Drug Discovery & CMC | 0 | N/A |
| Marc Fellous | Senior VP and Head of Clinical Development & Medical Affairs | 0 | N/A |
| Robert Ticktin | General Counsel, Chief Operating Officer & Company Secretary | 0 | 1962 |
| Tim Smith | Senior Vice President and Head of Corporate Development & Investor Relations | 0 | N/A |
| Crystal Zuckerman | Vice President of Human Resources | 0 | N/A |
| Laura De Leon | Vice President & Head of Clinical Operations | 0 | N/A |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.